References
- National Registry of Diseases Office. Singapore cancer registry annual report 2021. 2023. Available from: https://www.nrdo.gov.sg/docs/librariesprovider3/default-document-library/scr-ar-2021-web-report.pdf?sfvrsn=591fc02c_0.
- Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. BMC Med. 2019;17(1):90. doi: 10.1186/s12916-019-1326-5
- Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176–198. doi: 10.1158/2159-8290.CD-18-1177
- Health Sciences Authority (HSA) Singapore. Summary Report of Benefit-Risk Assessment [Internet] Package insert for sacituzumab govitecan (Trodelvy), p. 15–35. revised Jan 2022. Available from: https://www.hsa.gov.sg/docs/default-source/hprg-tpb/summary-reports/trodelvy_summary-report_31january2022.pdf?sfvrsn=4cfc7f9d_2
- Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529–1541.
- Gradishar WJ, Moran MS, Abraham J, et al. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023;21(6):594–608.
- Gennari A, André F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–1495.
- Pearce F, Lin L, Teo E, et al. Health Technology Assessment and its use in drug policies: Singapore. Value Health Reg Issues. 2019;18:176–183. doi: 10.1016/j.vhri.2018.03.007
- Agency for Care Effectiveness. Drug and vaccine evaluation methods and process guide. Version 3.0 2021. Ministry Of Health, Singapore. Available from: https://www.ace-hta.gov.sg/resources/process-methods
- Cheng L-J, Wong G, Chay W-Y, et al. Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):441–448.
- Lang Y, Chai Q, Tao W, et al. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer. Breast. 2023;68:173–180. doi: 10.1016/j.breast.2023.02.003
- Xie J, Li S, Li Y, et al. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer. BMC Health Serv Res. 2023;23(1):706.
- Chen J, Han M, Liu A, et al. Economic evaluation of sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer in China and the US. Front Oncol. 2021;11:734594. doi: 10.3389/fonc.2021.734594
- National Institute for Health and Care Excellence. Sacituzumab govitecan for treating unresectable locally advanced or metastatic triple-negative breast cancer after 2 or more therapies 2022. Technology appraisal guidance [TA819]: supporting evidence. Available from: https://www.nice.org.uk/guidance/ta819/evidence
- Li X, Yang J, Peng L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017;161(2):279–287.
- Rohatgi A WebPlotdigitizer [Internet]. San Francisco (USA) 2022. Available from: http://www.automeris.io/WebPlotDigitizer
- Pharmaceutical Benefit Advisory Committee. November 2021 PBAC meeting with March 2022 addendum - SACITUZUMAB GOVITECAN, powder for injection 180mg. 2022. Available from: https://m.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2022-03/files/sacituzumab-govitecan-psd-march-2022.docx
- Wei Y, Royston P. Reconstructing time-to-event data from published Kaplan–Meier curves. Stata J. 2017;17(4):786–802. doi: 10.1177/1536867X1801700402
- National Institute for Health and Care Excellence. Sacituzumab govitecan for treating unresectable locally advanced or metastatic triple-negative breast cancer after 2 or more therapies 2022. Technology Appraisal Guidance [TA819]. Available from: https://www.nice.org.uk/guidance/ta819/
- Department of Statistics Singapore. Prices and price indices: Department of Statistics Singapore; [cited 2023 Jul 26]. Available from: https://www.singstat.gov.sg/find-data/search-by-theme/economy/prices-and-price-indices/latest-data
- Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683–690.
- Phua LC, Lee SC, Ng K, et al. Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer. BMC Health Serv Res. 2020;20(1):581.
- Agency for Care Effectiveness. Singapore healthcare resource sheet 2023. Available from: https://www.ace-hta.gov.sg/docs/default-source/company-led-submission/singapore-healthcare-resource-sheet-(mar-2023).xlsx?sfvrsn=2faa9fbc_6
- Loibl S, Loirat D, Tolaney S, et al. Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). ePoster display at: European Society for Medical Oncology Virtual Congress 2021. Ann Oncol. 2021;32(suppl_5):S457–S515.
- Longworth L, Yang Y, Young T, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Southampton (UK): NIHR Journals Library; 2014 Feb, (Health Technology Assessment. 18(9). Available from: https://www.ncbi.nlm.nih.gov/books/NBK261616/.